Related Experiment Videos
The effectiveness of labetalol compared to hydrochlorothiazide in hypertensive black patients
C Lucas1, P Jenkins, J Mendels
1Division of Preventive and Nutritional Medicine, William Beaumont Hospital, Birmingham, Michigan.
Insights
Labetalol and hydrochlorothiazide (HCTZ) showed similar efficacy in controlling hypertension in Black patients. Both drugs effectively lowered blood pressure, with no significant differences observed between the two treatments.
Area of Science:
- Cardiovascular medicine
- Pharmacology
Background:
- Hypertension is a significant health concern, particularly in Black populations.
- Labetalol and hydrochlorothiazide (HCTZ) are commonly prescribed antihypertensive medications.
Purpose of the Study:
- To compare the efficacy of labetalol and HCTZ in controlling hypertension among Black patients.
- To evaluate blood pressure reduction and heart rate changes in response to both drugs.
Main Methods:
- A prospective, double-blind study involving 61 adult patients with mild to moderate hypertension.
- Patients received either labetalol (100 mg twice daily) or HCTZ (25 mg twice daily) for 12 weeks.
- Doses were titrated up to 400 mg twice daily for labetalol and 50 mg twice daily for HCTZ if blood pressure control was not achieved.
Main Results:
- Both labetalol and HCTZ groups showed comparable mean decreases in standing diastolic blood pressure (10 mm Hg for labetalol vs. 10.1 mm Hg for HCTZ).
- No significant differences were found between the groups in reductions of standing blood pressure or heart rate.
- Blood pressure control was achieved in 63% of patients on labetalol and 58% on HCTZ.
Conclusions:
- Labetalol and HCTZ demonstrate similar efficacy in managing hypertension in Black patients.
- Both medications are effective in reducing blood pressure, with comparable outcomes in this patient population.
Abstract:
Labetalol and hydrochlorothiazide (HCTZ) were compared for their efficacy in controlling hypertension of blacks in a prospective, double-blind study. Sixty-one adult patients with mild to moderate hypertension (standing diastolic blood pressure greater than or equal to 95 mm Hg and less than or equal to 114 mm Hg) were randomly selected to receive either labetalol 100 mg twice daily (n = 30) or HCTZ 25 mg twice daily (n = 31). The study was divided into two phases: a 4-week placebo run-in phase, during which all previous antihypertensive medication was discontinued, and a 12-week drug treatment phase. Labetalol and HCTZ doses were titrated to 400 mg twice and 50 mg twice daily, respectively, during the first 6 weeks of the drug treatment phase for those patients not achieving blood pressure control (standing diastolic blood pressure less than 90 mm Hg and a decrease of 10 mm Hg from baseline) on initial dosages. By the end of the 12 weeks of drug administration, patients on labetalol experienced a mean decrease of 10 mm Hg in standing diastolic blood pressure compared to a mean decrease of 10.1 mm Hg in patients on HCTZ. No differences were observed between the two treatment groups in reductions of either standing blood pressure or heart rate. While 19 of 30 patients on labetalol (63%) achieved blood pressure control at some point during the study with a mean daily dose of 568 mg, 18 of 31 (58%) HCTZ-treated patients achieved control with a mean daily dose of 72 mg.(ABSTRACT TRUNCATED AT 250 WORDS)